Checkpoint Capital L.P. Buys 22,500 Shares of argenex SE $ARGX

Key Points

• Checkpoint Capital L.P. increased its stake in argenex SE by 24.3% during the first quarter, owning 115,000 shares after acquiring an additional 22,500 shares, making argenex its largest position.
• argenex recently reported earnings of $3.74 EPS, surpassing expectations, with revenues reaching $866.79 million, compared to analysts' predictions of $776.82 million.
• Various analysts have set bullish price targets for argenex, with prices ranging from $680.00 to $820.00, and a consensus rating of "Buy" among analysts.

Checkpoint Capital L.P. lifted its stake in shares of argenex SE (NASDAQ:ARGX - Free Report) by 24.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 115,000 shares of the company's stock after purchasing an additional 22,500 shares during the quarter. argenex comprises 37.3% of Checkpoint Capital L.P.'s portfolio, making the stock its largest position. Checkpoint Capital L.P. owned approximately 0.19% of argenex worth $68,064,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rakuten Securities Inc. grew its holdings in argenex by 56.4% in the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after buying an additional 22 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in argenex in the 4th quarter worth approximately $38,000. WPG Advisers LLC bought a new position in argenex in the 1st quarter worth approximately $37,000. Golden State Wealth Management LLC bought a new position in argenex in the 1st quarter worth approximately $44,000. Finally, Brooklyn Investment Group grew its holdings in argenex by 102.7% in the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company's stock worth $44,000 after buying an additional 38 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ARGX has been the subject of a number of recent analyst reports. Jefferies Financial Group set a $818.00 price objective on argenex and gave the stock a "buy" rating in a report on Tuesday, August 26th. Piper Sandler increased their price objective on argenex from $750.00 to $820.00 and gave the stock an "overweight" rating in a report on Tuesday, August 26th. Wedbush reissued an "outperform" rating and issued a $800.00 price objective on shares of argenex in a report on Monday, August 25th. Robert W. Baird upgraded argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price target on the stock in a research report on Tuesday, May 13th. Finally, Baird R W upgraded argenex from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating and twenty-one have given a Buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $772.84.

argenex Stock Up 2.2%

ARGX opened at $722.01 on Thursday. The firm has a market cap of $44.19 billion, a PE ratio of 37.03, a P/E/G ratio of 0.81 and a beta of 0.41. The business has a fifty day simple moving average of $620.60 and a 200-day simple moving average of $601.21. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $723.28.

argenex (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, topping the consensus estimate of $2.84 by $0.90. The business had revenue of $866.79 million during the quarter, compared to analysts' expectations of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%. On average, equities research analysts anticipate that argenex SE will post 3.13 EPS for the current fiscal year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.